6-chloro-2-methyl-5-(prop-2-en-1-yl)pyrimidin-4-amine

Compound number
MolPort-002-545-067
IUPAC
6-chloro-2-methyl-5-(prop-2-en-1-yl)pyrimidin-4-amine
IUPAC traditional
6-chloro-2-methyl-5-(prop-2-en-1-yl)pyrimidin-4-amine
SMILES
Cc1nc(N)c(CC=C)c(Cl)n1
InChI key
PMNLBPKZOWXYIE-UHFFFAOYSA-N
Molecular formula
Molecular weight
183.64
Solubility
not available

Marketplace Offers

Vitas M Chemical Limited

Direct S&H to USA:
220.00 USD
Catalog
Screening compound
Ships out
15 business days
Purity
>90%
Last updated
this week
In warehouse
55.00 mg

Supplier Catalogue Data

Pack size Ships out Price Quantity
1 mg September 9, 2022 30.22 USD
Add to Cart Buy
2 mg September 9, 2022 33.07 USD
Add to Cart Buy
3 micromol September 9, 2022 31.00 USD
Add to Cart Buy

INTERBIOSCREEN DOO BAR

Direct S&H to USA:
220.00 USD
Catalog
Screening compound
Ships out
15 business days
Purity
92 - 98%
Last updated
last week
In warehouse
55.00 mg

Supplier Catalogue Data

Pack size Ships out Price Quantity
3 micromol September 9, 2022 39.60 USD
Add to Cart Buy
5 micromol September 9, 2022 50.40 USD
Add to Cart Buy
10 micromol September 9, 2022 85.50 USD
Add to Cart Buy

Get your compounds in the right format

Molport Reweighting and Reformatting Services

More Information

Compound identifiers

Compound number
MolPort-002-545-067

Names, Synonyms and 3rd Party Identifiers

Name
5-allyl-6-chloro-2-methylpyrimidin-4-amine
6-chloro-2-methyl-5-(prop-2-en-1-yl)pyrimidin-4-amine

InChI

InChI
1/C8H10ClN3/c1-3-4-6-7(9)11-5(2)12-8(6)10/h3H,1,4H2,2H3,(H2,10,11,12)
InChI key
PMNLBPKZOWXYIE-UHFFFAOYSA-N

Formula

Molecular formula
C8H10ClN3
Molecular weight
183.64

Molport Guarantee

When you purchase products through the Molport website from any seller other than Molport itself, you will be protected by the Molport Guarantee. If you purchase products from Molport itself, this Molport Guarantee will not apply, and your remedies will be governed by the Molport Terms of Sale and Supply.

We use cookies to improve your experience on our websites and for advertising. By clicking "Accept All", you consent to our use of cookies. Learn more.

Feedback